FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1526173679> ?p ?o ?g. }

• W1526173679 endingPage "8S" @default.
• W1526173679 startingPage "3922S" @default.
• W1526173679 abstract "The locoregional application of tumor-specific antibodies conjugated with highly cytotoxic alpha-emitters is a promising new strategy for therapy of i.p. tumor cell dissemination. Using this approach, an antibody specifically targeting diffuse-type gastric cancer cells was coupled to the high linear energy transfer alpha-emitter (213)Bi for treatment of i.p. tumor cell spread in a nude mouse model.Nude mice were inoculated with HSC45-M2 human gastric cancer cells expressing mutant d9-E-cadherin. Twenty-four h after cell inoculation, mice received i.p. injections of either (213)Bi-d9MAb specifically binding to mutant d9-E-cadherin of HSC45-M2 cells or unspecific (213)Bi-d8MAb (7.4 or 22.2 MBq). Survival of treated animals was monitored compared with controls that had been injected with nonlabeled monoclonal antibody (MAb) or saline. Toxicity was evaluated by WBC counts after injection of 1.85, 7.4, or 22.2 MBq and analysis of chromosomal aberrations of bone marrow cells after injection of 7.4, 14.8, or 22.2 MBq.Survival rates of control mice and of mice treated with (213)Bi-MAbs differed significantly: the mean survival of untreated controls and mice that were given the nonlabeled antibody was 23 and 26 days. After injection of 22.2 MBq of the specific (213)Bi-d9MAb or the unspecific (213)Bi-d8MAb, mean survival was at least 143 or 130 days, respectively. Treatment with 7.4 MBq of (213)Bi-d9MAb increased mean survival to at least 232 days and with (213)Bi-d8MAb to at least 172 days. WBC counts decreased within 2 days after (213)Bi-therapy but reached pretreatment values between day 14 and 21 after activity injection. Chromosomal aberrations in bone marrow cells could only be detected at day 1 after (213)Bi-therapy. The frequency of chromosomal damages increased depending on the applied (213)Bi-activity.The therapeutic efficacy of the (213)Bi-d9MAb together with a low bone marrow toxicity support the locoregional therapy for that subgroup of diffuse-type gastric carcinoma patients expressing d9-E-cadherin." @default.
• W1526173679 created "2016-06-24" @default.
• W1526173679 creator A5000481071 @default.
• W1526173679 creator A5001001811 @default.
• W1526173679 creator A5005390795 @default.
• W1526173679 creator A5021198297 @default.
• W1526173679 creator A5052995463 @default.
• W1526173679 creator A5054626795 @default.
• W1526173679 creator A5065576952 @default.
• W1526173679 creator A5067025970 @default.
• W1526173679 creator A5072251082 @default.
• W1526173679 creator A5077879000 @default.
• W1526173679 creator A5081860768 @default.
• W1526173679 date "2003-09-01" @default.
• W1526173679 modified "2023-10-16" @default.
• W1526173679 title "Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody." @default.
• W1526173679 cites W1959428162 @default.
• W1526173679 cites W1963646933 @default.
• W1526173679 cites W1966241991 @default.
• W1526173679 cites W1967599173 @default.
• W1526173679 cites W1970536180 @default.
• W1526173679 cites W1985722657 @default.
• W1526173679 cites W1985950738 @default.
• W1526173679 cites W1985966082 @default.
• W1526173679 cites W1997928845 @default.
• W1526173679 cites W2000209715 @default.
• W1526173679 cites W2010150699 @default.
• W1526173679 cites W2042550029 @default.
• W1526173679 cites W2043319149 @default.
• W1526173679 cites W2046043957 @default.
• W1526173679 cites W2053162525 @default.
• W1526173679 cites W2055752560 @default.
• W1526173679 cites W2055895712 @default.
• W1526173679 cites W2057233809 @default.
• W1526173679 cites W2080585386 @default.
• W1526173679 cites W2094875122 @default.
• W1526173679 cites W2096057211 @default.
• W1526173679 cites W2123953807 @default.
• W1526173679 cites W2123987346 @default.
• W1526173679 cites W2127901889 @default.
• W1526173679 cites W2152982472 @default.
• W1526173679 cites W2163040193 @default.
• W1526173679 cites W2171140185 @default.
• W1526173679 cites W2324600853 @default.
• W1526173679 cites W2406806003 @default.
• W1526173679 cites W2738973011 @default.
• W1526173679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14506190" @default.
• W1526173679 hasPublicationYear "2003" @default.
• W1526173679 type Work @default.
• W1526173679 sameAs 1526173679 @default.
• W1526173679 citedByCount "12" @default.
• W1526173679 countsByYear W15261736792014 @default.
• W1526173679 countsByYear W15261736792018 @default.
• W1526173679 crossrefType "journal-article" @default.
• W1526173679 hasAuthorship W1526173679A5000481071 @default.
• W1526173679 hasAuthorship W1526173679A5001001811 @default.
• W1526173679 hasAuthorship W1526173679A5005390795 @default.
• W1526173679 hasAuthorship W1526173679A5021198297 @default.
• W1526173679 hasAuthorship W1526173679A5052995463 @default.
• W1526173679 hasAuthorship W1526173679A5054626795 @default.
• W1526173679 hasAuthorship W1526173679A5065576952 @default.
• W1526173679 hasAuthorship W1526173679A5067025970 @default.
• W1526173679 hasAuthorship W1526173679A5072251082 @default.
• W1526173679 hasAuthorship W1526173679A5077879000 @default.
• W1526173679 hasAuthorship W1526173679A5081860768 @default.
• W1526173679 hasConcept C121608353 @default.
• W1526173679 hasConcept C126322002 @default.
• W1526173679 hasConcept C142724271 @default.
• W1526173679 hasConcept C159654299 @default.
• W1526173679 hasConcept C203014093 @default.
• W1526173679 hasConcept C2776146153 @default.
• W1526173679 hasConcept C2780007613 @default.
• W1526173679 hasConcept C2780159080 @default.
• W1526173679 hasConcept C502942594 @default.
• W1526173679 hasConcept C542903549 @default.
• W1526173679 hasConcept C71924100 @default.
• W1526173679 hasConceptScore W1526173679C121608353 @default.
• W1526173679 hasConceptScore W1526173679C126322002 @default.
• W1526173679 hasConceptScore W1526173679C142724271 @default.
• W1526173679 hasConceptScore W1526173679C159654299 @default.
• W1526173679 hasConceptScore W1526173679C203014093 @default.
• W1526173679 hasConceptScore W1526173679C2776146153 @default.
• W1526173679 hasConceptScore W1526173679C2780007613 @default.
• W1526173679 hasConceptScore W1526173679C2780159080 @default.
• W1526173679 hasConceptScore W1526173679C502942594 @default.
• W1526173679 hasConceptScore W1526173679C542903549 @default.
• W1526173679 hasConceptScore W1526173679C71924100 @default.
• W1526173679 hasIssue "10 Pt 2" @default.
• W1526173679 hasLocation W15261736791 @default.
• W1526173679 hasOpenAccess W1526173679 @default.
• W1526173679 hasPrimaryLocation W15261736791 @default.
• W1526173679 hasRelatedWork W1971189917 @default.
• W1526173679 hasRelatedWork W1989050701 @default.
• W1526173679 hasRelatedWork W2000976667 @default.
• W1526173679 hasRelatedWork W2016479862 @default.
• W1526173679 hasRelatedWork W2091011349 @default.
• W1526173679 hasRelatedWork W2100027804 @default.
• W1526173679 hasRelatedWork W2111931758 @default.

• next